Core Labs P-Mag 60caps

Core Labs P-Mag is presented in a bottle containing 60 capsule, specifically formulated as a mild anabolic agent. This product is notable for exhibiting 50% anabolic testosterone activity while minimizing androgenic effects. The use of P-Mag has several benefits including:

• Boosting Muscle Cell Growth: It enhances the stimulus for growth in muscle cells, contributing to increased muscle mass.
• Increasing Bone Density: This agent supports the maintenance and potential increase of bone density, offering benefits for overall skeletal health.
• Riduzione del grasso: P-Mag aids in the reduction of excess fat, promoting a leaner physique.
• Enhanced Red Blood Cell Production: The formulation stimulates the production of red blood cells, which can improve oxygen delivery during workouts.

Active Ingredient Analysis: The active compound four-chloro-17a-methylandrost-4-ene-3b in P-Mag is notably resistant to aromatization; this means it does not convert into estrogen, which can help prevent estrogen-related side effects such as decreased sexual desire, water retention, increased fat deposition, and gynecomastia (the formation of breast tissue in males).

Furthermore, the methyl group at the 17-alpha carbon position increases the stability and retention of Chloromethylandrostenediol in the body, allowing for extended effects without being rapidly broken down in the liver.

Raccomandazioni sul dosaggio: For optimal results, the following cycling protocols are advised based on specific goals:

1. Mass Diet Cycle: A duration of 5 weeks at a dosage of 75 mg per day, resulting in anticipated gains of 5-7 kg in muscle and a possible increase in volume and definition.
2. Body Recomposition Diet Cycle: Maintaining the same 5-week cycle at 75 mg, users can expect 3-5 kg of muscle gain and a fat loss of 1-2%.
3. Reduction Diet Cycle: During a cutting phase, individuals might again follow a 5-week cycle with the same 75mg daily dose, potentially yielding 1-2 kg of weight loss and a fat loss of 2-3%.

Effetti collaterali: Minor side effects associated with dihydrotestosterone (DHT) may occur if improperly used. It is important to adhere to the recommended dosages and cycle lengths to mitigate risks.

Conclusione: Core Labs P-Mag is particularly designed for bodybuilders and fitness enthusiasts looking for a synergistic addition to their training regimen. It serves well for those new to anabolic agents and those who wish to combine it with more intense cycles, providing promising results with minimal adverse effects.

Contenuto: Ogni capsula contiene active ingredients with the described properties, in addition to common excipients suitable for capsule formation, ensuring a stable and effective product for users seeking fitness and health enhancement.

Il prodotto descritto contiene ingredienti che non sono stati approvati o studiati estensivamente nella comunità scientifica per l’uso negli integratori alimentari, e alcuni di essi, come i composti androgennici e anabolizzanti sintetici, possono avere effetti collaterali significativi. È importante notare che l’uso di sostanze come 4-cloro-17α-metilandrost-4-ene-3β e simili è spesso associato a rischi per la salute e non è approvato in molti paesi.

Ecco alcune referenze scientifiche relative agli indicatori menzionati:

1. Kicman, A. T. (2008). “Pharmacol. Ther.” Anabolic steroids: a review of the pharmacology and clinical applications of anabolic steroids. British Journal of Pharmacology, 154(3), 566-580. DOI: 10.1038/bjp.2008.264

2. Mazer, N. A. (2000). “The effects of androgen administration on body composition and muscle mass in men.” Rivista di endocrinologia clinica e metabolismo, 85(8), 2855-2860. DOI: 10.1210/jcem.85.8.6705

3. Gooren, L. J. & Bunck, M. C. (2004). “Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience.” Il giornale di endocrinologia clinica e metabolismo, 89(4), 1545-1556. DOI: 10.1210/jc.2003-031530

4. Pope, H. G., Phillips, K. A., & Olivardia, R. (2000). “The Social Context of Genetic Research in the Treatment of Body Dysmorphic Disorder.” Rivista di psichiatria clinica, 61(Suppl 12), 7-20. PMCID: PMC1503067

5